Search | Clinical Trials Finder

Conditions: Urinary Bladder Neoplasms
Interventions: Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more

Conditions: Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions: PLZ4-coated paclitaxel loaded micelles (PPM); Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Bladder Cancer
Interventions: BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Bladder Cancer
Interventions: Mitomycin C, Chemophase; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 5
States / cities: Phoenix, Arizona • La Mesa, California • Gainesville, Florida + 2 more

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test; Procedure · Diagnostic Test
Lead sponsor: White River Junction Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: West Haven, Connecticut • Bay Pines, Florida • Tampa, Florida + 7 more

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: CG0070; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Urinary Tract Infections, Bladder Cancer
Interventions: Vikor Scientific Urine-IDTM; Diagnostic Test
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
Interventions: BGJ398; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Muscle Invasive Bladder Cancer
Interventions: CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: La Jolla, California • Orange, California • Tampa, Florida + 9 more

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 136
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 94 more

Conditions: Bladder Cancer
Interventions: Intravenous MK-3475/ Intravesical BCG; Drug
Lead sponsor: Southern Illinois University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Springfield, Illinois • Detroit, Michigan

Conditions: Bladder Cancer
Interventions: Atezolizumab, Bacille Calmette-Guérin; Drug · Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Bladder Cancer
Interventions: bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy; Biological · Drug · Procedure
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 4
States / cities: Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more

Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions: TARA-002, Investigator's Choice of Intravesical Chemotherapy; Drug
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Queen Creek, Arizona • Little Rock, Arkansas • Bakersfield, California + 5 more

Conditions: Bladder Cancer
Interventions: Avelumab, BCG; Drug · Biological
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Urothelial Carcinoma of the Urinary Bladder
Interventions: Cabazitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: Guarionex J. Decastro; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer
Interventions: Nivolumab, Ipilimumab, Radical cystectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Bladder Cancer
Interventions: CG0070; Biological
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 13 more

Conditions: Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration; Drug · Combination Product
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 8 more

Conditions: Bladder Cancer
Interventions: Apaziquone, Placebo; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 28
States / cities: Glendale, Arizona • Phoenix, Arizona • Laguna Woods, California + 24 more

Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions: Intismeran autogene, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more

Conditions: Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Omaha, Nebraska • Philadelphia, Pennsylvania

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8); Drug · Radiation · Biological + 1 more
Lead sponsor: Noah Hahn, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Bladder Cancer, High Grade, Non Muscle Invasive
Interventions: oncolytic adenovirus expressing GMCSF; Biological
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

MK-3475/BCG in High Risk Superficial Bladder Cancer

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer